Monopar Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Monopar Therapeutics

14/05/2022 24:39

* Monopar Therapeutics Inc  MNPR.OQ  reported a quarterly
adjusted
loss of 19 cents​​ per share for the quarter ended in March. The
mean expectation of five analysts for the quarter was for a loss
of 22 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Monopar Therapeutics Inc's reported EPS for the quarter
was a
loss of 19 cents​.
    * The mean earnings estimate of analysts had risen by
about 7.3%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Monopar Therapeutics Inc shares had fallen by 27.5% this
quarter and lost 42.4% so far this year.
    * The company reported a quarterly loss of $2.46 million.
    * Wall Street's median 12-month price target for Monopar
Therapeutics Inc is $22.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 13 at 11:39 p.m.  ​All
figures in US dollars unless otherwise stated